Fe3+@polyDOPA-b-polysarcosine, a T1-Weighted MRI Contrast Agent Via Controlled NTA Polymerization.

Yuedong Miao,Fengnan Xie,Jiayu Cen,Fei Zhou,Xinfeng Tao,Jingfeng Luo,Guocan Han,Xianglei Kong,Xiaoming Yang,Jihong Sun,Jun Ling
DOI: https://doi.org/10.1021/acsmacrolett.8b00287
IF: 5.8
2018-01-01
ACS Macro Letters
Abstract:alpha-Amino acid N-thiocarboxyanhydrides (NTAs) are promising cyclic monomers to synthesize polypeptides and polypeptoids via controlled ring-opening polymerizations. Superior to N-carboxyanhydrides requiring protection on hydroxyl groups, NTAs are able to tolerate such nucleophiles. In this work, we report the synthesis of NTA monomers containing unprotected phenolic hydroxyl groups of 3,4-dihydroxy-L-phenylalanine (DOPA) and L-tyrosine (Tyr). Their controlled ROPs and sequential copolymerizations with polysarcosine (PSar) yield PDOPA, PTyr, and PDOPA-b-polysarcosine (PDOPA-b-PSar) products quantitatively with designable degrees of polymerization. Micellar nanoparticles of Fe3+@PDOPA-b-PSar have been prepared thanks to the strong chelation of iron(III) cation by catechol ligands that act as T1-weighted magnetic resonance imaging (MRI) contrast agents. For instance, Fe3+@PDOPA(10)b-PSar(50) exhibits higher longitudinal relaxivity (r(1) = 5.6 mM(-1) s(-1)) than commercial Gd3+-based compounds. Effective MRI contrast enhancement in vivo of nude mice with a moderate duration (150 min) and 3D magnetic resonance angiography in rabbit illustrated by using volume rendering and maximal intensity projection techniques ignite the clinical application of Fe3+-based polypept(o)ides in diagnostic radiology as Gd-free MRI contrast agents.
What problem does this paper attempt to address?